Johnson & Johnson $JNJ is Atlas Brown Inc.’s 9th Largest Position

Atlas Brown Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,544 shares of the company’s stock after selling 172 shares during the quarter. Johnson & Johnson comprises approximately 1.7% of Atlas Brown Inc.’s portfolio, making the stock its 9th biggest position. Atlas Brown Inc.’s holdings in Johnson & Johnson were worth $5,277,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Martin Capital Partners LLC increased its holdings in shares of Johnson & Johnson by 211.5% during the second quarter. Martin Capital Partners LLC now owns 44,302 shares of the company’s stock valued at $6,767,000 after acquiring an additional 30,079 shares in the last quarter. Richard P Slaughter Associates Inc boosted its position in Johnson & Johnson by 8.2% in the second quarter. Richard P Slaughter Associates Inc now owns 7,866 shares of the company’s stock worth $1,202,000 after purchasing an additional 596 shares during the last quarter. Canandaigua National Bank & Trust Co. boosted its position in Johnson & Johnson by 4.8% in the second quarter. Canandaigua National Bank & Trust Co. now owns 95,686 shares of the company’s stock worth $14,616,000 after purchasing an additional 4,392 shares during the last quarter. Paladin Wealth LLC grew its stake in shares of Johnson & Johnson by 6.3% during the 2nd quarter. Paladin Wealth LLC now owns 5,515 shares of the company’s stock valued at $842,000 after acquiring an additional 326 shares during the period. Finally, RMR Wealth Builders grew its stake in shares of Johnson & Johnson by 6.9% during the 2nd quarter. RMR Wealth Builders now owns 5,184 shares of the company’s stock valued at $792,000 after acquiring an additional 333 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 0.2%

Shares of NYSE JNJ opened at $178.10 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The business has a fifty day moving average price of $170.81 and a 200 day moving average price of $161.27.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Guggenheim reissued a “neutral” rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Bank of America boosted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.